Associate Director, Market Access Analytics
Madrigal Pharmaceuticals Inc - 2 Locations
Posted Oct 27, 2026
Benefits
- Parental leave
- Not verified
- Non-birth-parent leave
- Not verified
- Family-building benefits
-
- Fertility benefits: Not verified
- Adoption assistance: Not verified
- Surrogacy assistance: Not verified
- Mental health support
- Offered From the posting source checked Nov 17, 2026
- Relocation assistance
- Not verified
- Childcare support
- Not verified
- Learning budget
- Not verified
- Verification
- Not verified checked Nov 20, 2026
- Salary
- $208K-$208K From the posting source checked Nov 17, 2026
- 401(k) match
- Reported from DOL Form 5500 industry filing (not employer-specific)
Was this benefit information wrong? Tell us.
Market context
- U.S. role benchmark (BLS OEWS)
- $111,944 U.S. median for this role
- Projected growth (BLS Employment Projections)
- +13.7% - Much faster than average
U.S. benchmark only; posted salary is not compared across countries or currencies.
Matched to SOC 15-1252 - Data and ML aggregate by role bucket.
Source:U.S. Bureau of Labor Statistics, OEWS, May 2024andEmployment Projections, 2024-2034.
Role
Schedule
- Shift type
- Not verified
- Weekend work
- Not verified
Company
- Equity
- Offered Verified - SEC 10-K source checked Nov 17, 2026
Application
- Cover letter
- Not verified
- Assessment
- Not verified
- Deadline
- Not stated
Where they hire
State eligibility is not yet verified.
About this role
Associate Director, Market Access Analytics 2 Locations Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Associate Director, Market Access Analytics leads payer, formulary, and coverage analytics for Madrigal's Commercial organization, turning access and contracting data into insight that guides Market Access strategy for the MASH portfolio. Reporting to the Senior Director, Market Access, Trade & IDN Analytics, this role owns the payer analytics and reporting agenda - measuring formulary access, coverage, utilization management, and contract performance at national and sub-national levels - and serves as a trusted analytics partner to Managed Markets, Patient
Read the full description at madrigalpharma.wd501.myworkdayjobs.com. FewerJobs shows a preview and links to the original posting.
Apply link verified; last checked Nov 20, 2026.
What verified means
Verified means a displayed claim has field-level provenance to a source FewerJobs pulled: a government or employer source, or the original job posting. Posting-sourced facts are employer-stated and are labeled separately from government records.
Related jobs
Associate Director, Orchestration Analytics & Products
Madrigal Pharmaceuticals Inc - 2 Locations
Director, Market Access Analytics
Revolution Medicines - Redwood City, California, United States
Associate Director, Biostatistics
Ironwood Pharma Inc - Basel, Switzerland
Associate Director, Market Access Analytics - Neurology
Regeneron Pharmaceuticals - SLEEPY HOLLOW